Shareholders Approve Issuance of 4.2M Shares from Warrant Exercises
TPST is trading near its 52-week low of $1.22 (3.3% above the low) on light trading volume (0.1× avg).
Summary
Shareholders approved the issuance of up to 4.2 million shares from warrant exercises, providing a crucial capital-raising pathway for the financially distressed company.
Key Events · Financing and Capital Events · TPST
-
Shareholder Approval for Warrant Exercises
Stockholders approved the issuance of up to 1,851,854 shares of common stock upon the exercise of outstanding Series A and Series B Warrants, which were issued in connection with a private placement offering dated March 20, 2026.
-
Additional Warrant Exercise Approval
Stockholders also approved the issuance of up to 2,344,828 shares of common stock upon the exercise of outstanding Common Warrants, issued in connection with an Inducement Offer to Exercise Common Stock Purchase Warrants from November 2025.
-
Significant Potential Dilution
The combined approvals authorize the potential issuance of approximately 4.2 million shares, representing substantial potential dilution for existing shareholders.
-
Critical Capital Infusion Mechanism
This approval provides a vital mechanism for Tempest Therapeutics to raise capital, addressing its 'going concern' warning, low cash position, and Nasdaq compliance issues.
Analysis · TPST · Life Sciences
This approval allows Tempest Therapeutics to issue up to 4.2 million shares upon the exercise of outstanding warrants, representing significant potential dilution for existing shareholders. Given the company's 'going concern' warning, low cash reserves, and Nasdaq deficiency notices, this mechanism for capital infusion is critical for its financial viability and continued operations, especially as it trades near 52-week lows.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.4% of the 1304 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPST was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.5M. The 52-week trading range was $1.22 to $12.23. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.